Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 3, 2013, Pages 533-539

  Mendivil, Alberto A ^a   Micha, John P ^a   Brown, John V ^a   Rettenmaier, Mark A ^a   Abaid, Lisa N ^a   Lopez, Katrina L ^b   Goldstein, Bram H ^a  

^a Gynecologic Oncology Associates   (United States)

^b Women's Cancer Research Foundation   (United States)

Author keywords

Carboplatin; Chemotherapy; Gynecologic oncology; Ovarian cancer; Paclitaxel; Vorinostat

Indexed keywords

CARBOPLATIN; PACLITAXEL; VORINOSTAT;

ADULT; AGED; ANASTOMOSIS; ANEMIA; ARTICLE; CLINICAL ARTICLE; COLON FISTULA; COLON RESECTION; DEHYDRATION; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; INTESTINE PERFORATION; KIDNEY FAILURE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVARY CARCINOMA; PANCYTOPENIA; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECTOVAGINAL FISTULA; SMALL INTESTINE OBSTRUCTION; SMALL INTESTINE RESECTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; HYDROXAMIC ACIDS; INCIDENCE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84876268623     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31828566f1     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. du Bois A, Herrstedt J, Hardy-Bessard AC, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010;28:4162-4169.
3. Micha JP, Goldstein BH, Rettenmaier MA, et al. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol. 2004;94:719-724.
4. Chobanian NH, Greenberg VL, Gass JM, et al. Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status. Anticancer Res. 2004;24:539-545.
5. Dietrich CS 3rd, Greenberg VL, DeSimone CP, et al. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecol Oncol. 2010;116:126-130.
6. Sonnemann J, Gange J, Pilz S, et al. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer. 2006;6:183.
7. Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. J Invest Dermatol. 2005;125:1045-1052.
8. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31-39.
9. Modesitt SC, Sill M, Hoffman JS, et al Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:182-186.
10. Cooper AL, Greenberg VL, Lancaster PS, et al. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol Oncol. 2007;104:596-601.
11. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The effect of maximal surgical cytoreduction on sensitivity to platinumtaxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008;108:276-281.
12. Brown JV, Rettenmaier MA, Dillman RA, et al. Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer. Gynecol Oncol. 1998;68:166-168.
13. Hainsworth JD, Greco F. Paclitaxel administered by 1-hour infusion. Cancer. 1994;74:1.
14. Calvert AH, Newell DR, Gunbrell LA. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756.
15. Jelliffe RW. Creatinine clearance: Bedside estimate. Ann Intern Med. 1973;79:605.
16. National Cancer Institute: Common Terminology Criteria for Adverse Events (version 4.03). Washington: National Institute of Health; 2010.
17. Therasse P, Arbuck SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92;205-216.
18. Rustin GJ, Marples M, Nelstrop AE. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res. 2004;10:3919-3926.
19. Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419-423.
20. Pan LN, Lu J, Huang B. HDAC inhibitors: A potential new category of anti-tumor agents. Cell Mol Immunol. 2007;4:337-343.
21. Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: Current applications and future perspectives for cancer therapy. Cancer Lett. 2009;280:201-210.
22. Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol. 2003;90:S8-S15.
23. Romanini A, Tanganelli L, Carnino F, et al. First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients. Gynecol Oncol. 2003;89:354-359.
24. Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 2007;17:771-776.
25. Colombo PE, Mourregot A, Fabbro M, et al. Aggressive surgical strategies in advanced ovarian cancer: A monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol. 2009;35:135-143.
26. Schorge JO, Eisenhauer EE, Chi DS. Current surgical management of ovarian cancer. Hematol Oncol Clin North Am. 2012;26:93-109.
27. Brown JV 3rd, Micha JP, Rettenmaier MA, et al. A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. Int J Gynecol Cancer. 2010;20:1132-1136.
28. Rose PG, Piver MS. Intestinal perforation secondary to paclitaxel. Gynecol Oncol. 1995;57:270-272.
29. Kim HS, Kim JW, Wu HG, et al. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate-or high-risk endometrioid endometrial cancer: A single institution experience. J Obstet Gynaecol Res. 2010;36:598-604.
30. de Haan D, van den Berg M. Colonic perforation secondary to taxol therapy: An unusual presentation. Onkologie. 2006;29:541-542.
31. Yardley DA, Raefsky E, Castillo R, et al. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer. Clin Breast Cancer. 2011;11:297-305.
32. LaBonte MJ, Wilson PM, Fazzone W, et al. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics. 2009;2:67.
33. Muraoka T, Tsukuda K, Toyooka S, et al. Ileal perforation induced by acute radiation injury under gefitinib treatment. Int J Clin Oncol. 2011;16:774-777.
34. Bruzzese F, Leone A, Rocco M, et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol. 2011;226:2378-2390.
35. Erjala K, Sundvall M, Junttila TT, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2006;12:4103-4111.
36. Uchida H, Maruyama T, Ono M, et al. Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology. 2007;148:896-902.
37. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-5186.
38. Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer. 2006;107:83-89.
39. Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol. 2007;107:118-123.